Chimeric Therapeutics presents very promising clinical trial data of its cancer treatment  

Be the First to Comment Read

Chimeric Therapeutics presents very promising clinical trial data of its cancer treatment  

Chimeric Therapeutics, clinical trials 
Image source: © Kwanchaidt |


  • Chimeric Therapeutics’ ongoing CLTX CAR T clinical trial has delivered promising results, suggesting it may be effective even against the most aggressive cancers.
  • Data highlights a 75% disease control rate at lowest dose level with up to 8 weeks of durability.
  • Tumour recurrence was prevented in the area where CLTX CAR T cells were infused, and tumour progression occurred in areas away from where CLTX CAR T cells were infused.
  • The generally well-tolerated adverse event profile of CLTX CAR T suggests no CRS events.
  • The Company plans to progress to more active dose levels with dual routes of administration.

Marking a major headway, Chimeric Therapeutics (ASX:CHM) has released encouraging data from its ongoing CLTX CAR T phase 1 clinical trial, suggesting regional control of tumour recurrence.

Recently, the Company participated in the Society for Neuro-Oncology (SNO) 26th annual scientific meeting and highlighted key additional clinical data during its final presentation of two CLTX CAR T abstracts on 20th November.

The CLTX CAR T phase 1 clinical trial is an ongoing single arm, open label trial in patients with MMP2+ recurrent or progressive glioblastoma. The prime objective is the safety evaluation of CLTX CAR T cells, determining the maximum tolerated dose schedule and a recommended dosing plan for Phase 2.

75% tumour control rate at the lowest dose

Abstract CTIM-29, “Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma” provided the initial clinical data insight for CLTX.

The Abstract CTIM-29 presented the clinical data from the ongoing phase 1 clinical trial, focusing on four patients enrolled in dose level 1 treated with 44 X 106 CLTX CAR T cells via a single method of intratumoral administration.

In the initial abstract presentation of patients treated at the 1st dose level, a disease control rate of 75% was obtained. Three out of the four patients treated achieved a best response of stable disease assessed by RANO criteria.

As per the additional insights as provided in the final presentation, the disease control observed was durable for around 5-8 weeks.

Under this trial, dose escalation is planned across four dose levels to a total dose of 440 X 106 CLTX CAR T cells administered through dual intratumoral and intraventricular routes of administration.

ALSO READ: Chimeric Therapeutics ticks off a crucial milestone; secures IND clearance for CHM 1101

Additional data suggests regional control of tumour regression

During the final presentation of CLTX CAR T CTIM-29 abstract, the Company presented MRI scans of patient 487, who was administered a dose of 44 X 106 CLTX CAR T cells through a single intratumoral route of administration, like all patients in this dose level.

The scans highlighted:

  • Tumour recurrence prevented in the left frontal lobe where CLTX CAR T cells were infused, two months after the infusion.
  • Tumour progression was seen only in the left temporal lobe which did not receive CLTX CAR T infusion.

These key findings reflect that the dual routes of administration of the CLTX CAR T cells in dose levels 2-4 may provide additional hope for patients.

The final presentation also included other information about the generally well-tolerated adverse event profile of CLTX CAR T. The data highlighted that CLTX CAR T was generally well tolerated with no observed cytokine release syndrome (CRS) and no dose limiting toxicities. CRS is an adverse event often related with CAR T cell therapy.

Additionally, the Company presented confirmation that the one grade 3 cerebral edema event was only possibly attributed to the CAR T cells. An adverse event, cerebral edema is commonly observed in glioblastoma patients.

The EXTH-10 abstract indicates key role of MMP2 expression  

Abstract EXTH-10, “Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells?” expanded on the translational understanding of Chlorotoxin (CLTX) activity.

The abstract presented early confirmation of the role of MMP-2 expression in CLTX CAR T tumour recognition and killing. It indicated that MMP-2 expression levels increased with tumour grade. Moreover, it was found that with higher MMP-2 expression, CLTX CART T cells preferentially kill tumour target cells.

The data suggests that the therapy may be effective even against the most aggressive cancers.

Within the presentation, early staining of a melanoma cell line was also shown, which validated strong MMP-2 expression and delivered early support to boost the clinical development program for CLTX CAR T into melanoma and other solid tumours.

MUST READ: Can Chimeric Therapeutics' CLTX CAR T therapy blaze a trail in GBM treatment?

Stock information: CHM shares were trading at AU$0.265 in the early hours of 30 November 2021.


Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK